Emerging therapeutic targets and preclinical models for severe asthma.

Galvão, I; Kim, RY; Shen, S; Budden, KF; Vieira, AT; Hansbro, PM

Emerging therapeutic targets and preclinical models for severe asthma.

Galvão, I Kim, RY Shen, S

Budden, KF Vieira, AT Hansbro, PM

Permalink

Publisher:: TAYLOR & FRANCIS LTD
Publication Type:: Journal Article
Citation:: Expert opinion on therapeutic targets, 2020, 24, (9), pp. 845-857
Issue Date:: 2020-09

Closed Access

	Filename	Description	Size
	Emerging therapeutic targets and preclinical models for severe asthma.pdf	Published version	2.99 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Galvão, I
dc.contributor.author	Kim, RY
dc.contributor.author	Shen, S https://orcid.org/0000-0002-1004-1936
dc.contributor.author	Budden, KF
dc.contributor.author	Vieira, AT
dc.contributor.author	Hansbro, PM
dc.date.accessioned	2020-11-23T02:30:23Z
dc.date.available	2020-11-23T02:30:23Z
dc.date.issued	2020-09
dc.identifier.citation	Expert opinion on therapeutic targets, 2020, 24, (9), pp. 845-857
dc.identifier.issn	1472-8222
dc.identifier.issn	1744-7631
dc.identifier.uri	http://hdl.handle.net/10453/144239
dc.description.abstract	INTRODUCTION:Asthma is a heterogeneous disease with complex multifactorial causes. It is possible to subclassify asthma into different phenotypes that have distinct immunological features. Eosinophilic asthma is a well-known phenotype of severe asthma; however, a large body of clinical and experimental evidence strongly associates persistent airway inflammation, including the accumulation of neutrophils in the bronchial mucosa, and resistance to corticosteroid therapy and non-Type-2 immune responses with severe asthma. Importantly, mainstay therapies are often ineffective in severe asthma and effective alternatives are urgently needed. AREAS COVERED:Here, we discussed recently developed mouse models of severe asthma that recapitulates key features of the disease in humans. We also provide findings from clinically relevant experimental models that have identified potential therapeutic targets for severe asthma. The most relevant publications on the topic of interest were selected from PubMed. EXPERT COMMENTARY:Increasing the understanding of disease-causing mechanisms in severe asthma may lead to the identification of novel therapeutic targets and the development of more effective therapies. Intense research interest into investigating the pathophysiological mechanisms of severe asthma has driven the development and interrogation of a myriad of mouse models that aim to replicate hallmark features of severe asthma in humans.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	TAYLOR & FRANCIS LTD
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation	http://purl.org/au-research/grants/nhmrc/1175134
dc.relation.ispartof	Expert opinion on therapeutic targets
dc.relation.isbasedon	10.1080/14728222.2020.1786535
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	0801 Artificial Intelligence and Image Processing, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Emerging therapeutic targets and preclinical models for severe asthma.
dc.type	Journal Article
utslib.citation.volume	24
utslib.location.activity	England
utslib.for	0801 Artificial Intelligence and Image Processing
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-11-23T02:30:10Z
pubs.issue	9
pubs.publication-status	Published
pubs.volume	24
utslib.citation.issue	9

Abstract:

INTRODUCTION:Asthma is a heterogeneous disease with complex multifactorial causes. It is possible to subclassify asthma into different phenotypes that have distinct immunological features. Eosinophilic asthma is a well-known phenotype of severe asthma; however, a large body of clinical and experimental evidence strongly associates persistent airway inflammation, including the accumulation of neutrophils in the bronchial mucosa, and resistance to corticosteroid therapy and non-Type-2 immune responses with severe asthma. Importantly, mainstay therapies are often ineffective in severe asthma and effective alternatives are urgently needed. AREAS COVERED:Here, we discussed recently developed mouse models of severe asthma that recapitulates key features of the disease in humans. We also provide findings from clinically relevant experimental models that have identified potential therapeutic targets for severe asthma. The most relevant publications on the topic of interest were selected from PubMed. EXPERT COMMENTARY:Increasing the understanding of disease-causing mechanisms in severe asthma may lead to the identification of novel therapeutic targets and the development of more effective therapies. Intense research interest into investigating the pathophysiological mechanisms of severe asthma has driven the development and interrogation of a myriad of mouse models that aim to replicate hallmark features of severe asthma in humans.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/144239